General Electric Company vs Novo Nordisk A/S: Strategic Comparison
Key Differences at a Glance
| Field | General Electric Company | Novo Nordisk A/S |
|---|---|---|
| Revenue | $45.9B | $46.0B |
| Founded | 1892 | 1989 |
| Employees | 57,000 | 69,505 |
| Market Cap | $353.5B | $550.0B |
| Headquarters | United States | Denmark |
Quick Stats Comparison
| Metric | General Electric Company | Novo Nordisk A/S |
|---|---|---|
| Revenue | $45.9B | $46.0B |
| Founded | 1892 | 1989 |
| Headquarters | Cincinnati, Ohio | Bagsvaerd, Denmark |
| Market Cap | $353.5B | $550.0B |
| Employees | 57,000 | 69,505 |
General Electric Company Revenue vs Novo Nordisk A/S Revenue — Year by Year
| Year | General Electric Company | Novo Nordisk A/S | Leader |
|---|---|---|---|
| 2025 | $45.9B | $46.0B | Novo Nordisk A/S |
| 2024 | $38.7B | $42.7B | Novo Nordisk A/S |
| 2023 | $35.3B | $34.0B | General Electric Company |
Business Model Breakdown
Overview: General Electric Company vs Novo Nordisk A/S
This in-depth comparison examines General Electric Company and Novo Nordisk A/S across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching General Electric Company on its own, evaluating Novo Nordisk A/S, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between General Electric Company and Novo Nordisk A/S is widest.
On the headline numbers, General Electric Company reports annual revenue of $45.9B against $46.0B for Novo Nordisk A/S, while their respective market capitalizations stand at $353.5B and $550.0B. General Electric Company is headquartered in United States and Novo Nordisk A/S operates from Denmark, and those different home markets shape how each company competes.
General Electric Company: GE's fiscal 2025 profile is a post-breakup aerospace story. Revenue reached $45.86 billion, net income attributable to GE was $8.70 billion, and the company reported a large installed engine base that feeds long-cycle service demand.
Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Business Models: How General Electric Company and Novo Nordisk A/S Make Money
General Electric Company and Novo Nordisk A/S pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between General Electric Company and Novo Nordisk A/S.
General Electric Company business model: GE Aerospace makes money by selling commercial and military engines, engine components, aerospace systems, and long-term service agreements. New engine sales can be cyclical and margin-light, but the installed base creates decades of service, spare-parts, repair, and overhaul revenue.
Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Competitive Advantage: General Electric Company vs Novo Nordisk A/S
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of General Electric Company stack up against those of Novo Nordisk A/S.
General Electric Company competitive advantage: GE Aerospace's advantage is the combination of certified engine technology, a massive installed base, CFM International scale, regulatory barriers, and global service infrastructure. Airlines and militaries do not switch engine ecosystems casually once fleets, maintenance tooling, and service agreements are in place.
Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Growth Strategy: Where General Electric Company and Novo Nordisk A/S Are Headed
Future prospects matter as much as current results. The growth strategies below explain how General Electric Company and Novo Nordisk A/S each plan to expand from here.
General Electric Company growth strategy: Growth comes from expanding the commercial engine installed base, converting more engines into long-term service agreements, raising service productivity, and investing in next-generation propulsion through programs such as CFM RISE and military engine development.
Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Financial Picture: General Electric Company vs Novo Nordisk A/S
A closer look at the financial trajectory of General Electric Company and Novo Nordisk A/S rounds out the comparison.
General Electric Company: Fiscal 2025 revenue was $45.86 billion, up from $38.70 billion in fiscal 2024. Net income attributable to GE was $8.70 billion, and GE Aerospace reported approximately 57,000 employees, including about 30,000 in the United States.
Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).
Company-Specific SWOT Notes
General Electric Company
With more than 44,000 commercial engines in operation globally under GE or CFM service relationships and a commercial services backlog of approximately $145 billion, GE Aerospace commands a recurring revenue base of extraordinary depth and durability.
Through the CFM International joint venture, GE Aerospace holds approximately 55 to 60 percent market share in the global narrowbody commercial engine market — the highest-volume segment of commercial aviation.
As the sole engine supplier for the Boeing 737 MAX through CFM International, GE Aerospace's commercial OE revenue is highly sensitive to Boeing's production cadence.
Despite significant progress under Culp's leadership, GE Aerospace carries residual legacy from the old GE's pension obligations and complex corporate history.
Global air passenger traffic surpassed 2019 pre-pandemic levels in 2024, and the International Air Transport Association projects compound annual growth of approximately 3.
China represents a significant percentage of global commercial aviation growth and a meaningful share of GE Aerospace's installed base and projected engine deliveries.
Novo Nordisk A/S
Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Novo Nordisk A/S | Novo Nordisk A/S reports the larger revenue base ($46.0B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | General Electric Company | Founded in 1892 vs 1989. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | General Electric Company | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Novo Nordisk A/S | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novo Nordisk A/S | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Novo Nordisk A/S reports the larger revenue base ($46.0B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1892 vs 1989. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: General Electric Company or Novo Nordisk A/S?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: General Electric Company vs Novo Nordisk A/S
Is General Electric Company better than Novo Nordisk A/S?
Verdict: Between General Electric Company and Novo Nordisk A/S, Novo Nordisk A/S is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Novo Nordisk A/S comes out ahead in this General Electric Company vs Novo Nordisk A/S comparison.
Who earns more — General Electric Company or Novo Nordisk A/S?
Novo Nordisk A/S earns more with $46.0B in annual revenue versus General Electric Company's $45.9B. Novo Nordisk A/S leads on total revenue based on latest verified figures.
Which company has higher revenue — General Electric Company or Novo Nordisk A/S?
General Electric Company reported $45.9B, while Novo Nordisk A/S reported $46.0B. The revenue leader is Novo Nordisk A/S based on latest verified figures.
General Electric Company revenue vs Novo Nordisk A/S revenue — which is higher?
General Electric Company revenue: $45.9B. Novo Nordisk A/S revenue: $45.9B. Novo Nordisk A/S has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: General Electric Company Annual Filings (10-K, 8-K)
- General Electric Company Corporate Website
- General Electric Company Annual Report 2025 - Revenue and Financial Data
- sec.gov
- data.sec.gov
- Novo Nordisk A/S Corporate Website
- Novo Nordisk A/S Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novonordisk.com